![conference banner](/images/conference-banner.jpeg)
Abstract
Obesity is widespread disease both in the developed and developing world, which currently affects over 300 million individuals worldwide and is associated with premature mortality and chronic morbidity. Although diet, physical activity and behavioral modifications should theoretically help in controlling this condition, very often these strategies are insufficient to normalize the multiple risks associated with this condition. Thus, pharmacological interventions for the treatment of this disease are essential. Paradoxically, the currently available drugs for the treatment of obesity are very few, their mechanism of action is hardly understood and their side effects are generally quite serious. Therefore, novel effective anti-obesity drugs possessing different mechanisms of action are needed. In this review we describe in detail a possible new approach for the treatment and prophylaxis of this disease based on the inhibition of Carbonic Anhydrases (CAs, EC 4..2.1.1), enzymes involved in several steps of de novo lipogenesis. In particular, we summarize here a series of kinetic and structural studies recently reported on Topiramate (TPM) and Zonisamide (ZNS), two antiepileptic drugs showing strong CA inhibitory properties, that were shown to induce persistent weight loss in obese patients. On the basis of the reviewed studies we suggest that the use of TPM and ZNS as lead molecules for the design of CA inhibitors targeting isozymes involved in lipogenesis could represent the beginning of a very promising approach for the treatment of obesity.
Keywords: zonisamide, topiramate, lipogenesis, carbonic anhydrase, Anti-obesity drugs
Current Pharmaceutical Design
Title: Are Carbonic Anhydrase Inhibitors Suitable for Obtaining Antiobesity Drugs ?
Volume: 14 Issue: 7
Author(s): Anna Di Fiore, Claudiu T. Supuran and Giuseppina De Simone
Affiliation:
Keywords: zonisamide, topiramate, lipogenesis, carbonic anhydrase, Anti-obesity drugs
Abstract: Obesity is widespread disease both in the developed and developing world, which currently affects over 300 million individuals worldwide and is associated with premature mortality and chronic morbidity. Although diet, physical activity and behavioral modifications should theoretically help in controlling this condition, very often these strategies are insufficient to normalize the multiple risks associated with this condition. Thus, pharmacological interventions for the treatment of this disease are essential. Paradoxically, the currently available drugs for the treatment of obesity are very few, their mechanism of action is hardly understood and their side effects are generally quite serious. Therefore, novel effective anti-obesity drugs possessing different mechanisms of action are needed. In this review we describe in detail a possible new approach for the treatment and prophylaxis of this disease based on the inhibition of Carbonic Anhydrases (CAs, EC 4..2.1.1), enzymes involved in several steps of de novo lipogenesis. In particular, we summarize here a series of kinetic and structural studies recently reported on Topiramate (TPM) and Zonisamide (ZNS), two antiepileptic drugs showing strong CA inhibitory properties, that were shown to induce persistent weight loss in obese patients. On the basis of the reviewed studies we suggest that the use of TPM and ZNS as lead molecules for the design of CA inhibitors targeting isozymes involved in lipogenesis could represent the beginning of a very promising approach for the treatment of obesity.
Export Options
About this article
Cite this article as:
Fiore Di Anna, Supuran T. Claudiu and Simone De Giuseppina, Are Carbonic Anhydrase Inhibitors Suitable for Obtaining Antiobesity Drugs ?, Current Pharmaceutical Design 2008; 14 (7) . https://dx.doi.org/10.2174/138161208783877820
DOI https://dx.doi.org/10.2174/138161208783877820 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Atrial Fibrillation and Chronic Kidney Disease in Hypertension: A Common and Dangerous Triad
Current Vascular Pharmacology Reactive Oxygen Species Formation by Polymorphonuclear Cells and Mononuclear Cells as a Risk Factor of Cardiovascular Diseases
Current Pharmaceutical Biotechnology Eplerenone, a New Selective Aldosterone Blocker
Current Pharmaceutical Design Poloxamer 188 (P188) as a Membrane Resealing Reagent in Biomedical Applications
Recent Patents on Biotechnology Editorial [“Current Aging Science”: An Important Platform for Reporting Advances in Aging-related Research]
Current Aging Science Reduction in Estimated Glomerular Filtration Rate (eGFR) Results in an Increased Risk of Spontaneous Hemorrhagic Transformation in Patients with Large-artery Atherosclerosis Stroke
Current Neurovascular Research Role of Unani Polyherbal Formulations in the Treatment of Diseases with Special Reference to Neurodegenerative Disorders
CNS & Neurological Disorders - Drug Targets Understanding and Avoiding Antiretroviral Adverse Events
Current Pharmaceutical Design Recombinant Protein Based Therapeutics for IPF
Inflammation & Allergy - Drug Targets (Discontinued) Mesothelioma - Epidemiology and Management
Current Respiratory Medicine Reviews The Endothelium and Platelets in Cardiovascular Disease: Potential Targets for Therapeutic Intervention
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Neuroprotective Role of Agmatine in Neurological Diseases
Current Neuropharmacology Is Atorvastatin Superior to Other Statins? Analysis of the Clinical Trials with Atorvastatin Having Cardiovascular Endpoints
Reviews on Recent Clinical Trials What Can Imaging Reveal about Obesity and the Brain?
Current Alzheimer Research Search for Obesity Drugs: Targeting Central and Peripheral Pathways
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Resuscitation of the Patient with the Functionally Univentricular Heart
Current Pediatric Reviews Q Fever Endocarditis
Infectious Disorders - Drug Targets Current Treatment of Psoriasis with Biologics
Current Drug Discovery Technologies Stem Cells: In Sickness and in Health
Current Stem Cell Research & Therapy Cardiovascular Effects of Modulators of Soluble Guanylyl Cyclase Activity
Cardiovascular & Hematological Agents in Medicinal Chemistry